U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

A new manufacturing plant in De Soto will be a Center of Excellence for the global company, along with expanded R&D ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Here’s what to know. In February, Merck officials presented to Delaware’s Council of Development Finance to make their case ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster ...

To keep up with growing demand, ​​Merck Animal Health will invest nearly $900 million to expand its manufacturing facility in ...

Merck is expanding domestic manufacturing with a $895 million investment in its Kansas factory, one of several major projects ...

Gov. Laura Kelly and Merck Animal Health — a veterinary medicine company — announced an $895 million expansion project at the ...

The animal health division of global pharmaceutical company Merck is doubling down on its operations in De Soto.